Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283009251> ?p ?o ?g. }
- W4283009251 abstract "Abstract Background The effectiveness of a 3 rd mRNA COVID-19 vaccine (“booster”) dose against the omicron (B.1.1.529) variant is uncertain especially in older, high-risk populations. Objective To determine mRNA booster vaccine effectiveness (VE) against SARS-CoV-2 infection, hospitalization and death in the omicron era by type of booster, type of primary vaccine, time since primary vaccine, age and comorbidity burden. Design Target trial emulation study comparing booster vaccination versus no booster. Setting U.S. Department of Veterans Affairs (VA) healthcare system Participants and Intervention Among persons who had received two mRNA COVID-19 vaccine doses at least 5 months earlier, we designed this retrospective matched cohort study to emulate a target trial of booster mRNA vaccination (BNT162b2 or mRNA-1273) versus no booster, conducted from 12/01/2021 to 03/31/2022. Measurements Booster VE. Results Each group included 490,838 well-matched persons, predominantly male (88%), mean age 63.0±14.0 years, followed for up to 121 days (mean 79.8 days). Booster VE >10 days after booster was 42.3% (95% CI 40.6-43.9) against SARS-CoV-2 infection, 53.3% (48.1-58.0) against SARS-CoV-2-related hospitalization and 79.1% (71.2-84.9) against SARS-CoV-2-related death. Booster VE was similar for different booster types (BNT162b2 or mRNA-1273), age groups or primary vaccination regimens, but was significantly higher with longer time since primary vaccination and with higher comorbidity burden. Limitations Predominantly male population. Conclusions Booster mRNA vaccination was highly effective in preventing death and moderately effective in preventing infection and hospitalization for up to 4 months after administration in the omicron era. Increased uptake of booster vaccination, which is currently suboptimal, should be pursued to limit the morbidity and mortality of SARS-CoV-2 infection, especially in persons with high comorbidity burden. Primary Funding Source: Department of Veterans Affairs" @default.
- W4283009251 created "2022-06-18" @default.
- W4283009251 creator A5017957195 @default.
- W4283009251 creator A5030337104 @default.
- W4283009251 creator A5030372642 @default.
- W4283009251 creator A5031243886 @default.
- W4283009251 creator A5031442179 @default.
- W4283009251 creator A5032332498 @default.
- W4283009251 creator A5033218952 @default.
- W4283009251 creator A5034269875 @default.
- W4283009251 creator A5054082399 @default.
- W4283009251 creator A5054727404 @default.
- W4283009251 creator A5054856356 @default.
- W4283009251 date "2022-06-16" @default.
- W4283009251 modified "2023-10-15" @default.
- W4283009251 title "Effectiveness of mRNA COVID-19 vaccine boosters against infection, hospitalization and death: a target trial emulation in the omicron (B.1.1.529) variant era" @default.
- W4283009251 cites W1547708675 @default.
- W4283009251 cites W1974338627 @default.
- W4283009251 cites W2009428399 @default.
- W4283009251 cites W2129168200 @default.
- W4283009251 cites W2298338128 @default.
- W4283009251 cites W3008905790 @default.
- W4283009251 cites W3045896100 @default.
- W4283009251 cites W3087377819 @default.
- W4283009251 cites W3102263761 @default.
- W4283009251 cites W3150333044 @default.
- W4283009251 cites W3163486615 @default.
- W4283009251 cites W3200511289 @default.
- W4283009251 cites W3215143364 @default.
- W4283009251 cites W4200274151 @default.
- W4283009251 cites W4206040938 @default.
- W4283009251 cites W4206069935 @default.
- W4283009251 cites W4207003944 @default.
- W4283009251 cites W4220661611 @default.
- W4283009251 cites W4220678484 @default.
- W4283009251 cites W4221072241 @default.
- W4283009251 doi "https://doi.org/10.1101/2022.06.15.22276466" @default.
- W4283009251 hasPublicationYear "2022" @default.
- W4283009251 type Work @default.
- W4283009251 citedByCount "2" @default.
- W4283009251 countsByYear W42830092512023 @default.
- W4283009251 crossrefType "posted-content" @default.
- W4283009251 hasAuthorship W4283009251A5017957195 @default.
- W4283009251 hasAuthorship W4283009251A5030337104 @default.
- W4283009251 hasAuthorship W4283009251A5030372642 @default.
- W4283009251 hasAuthorship W4283009251A5031243886 @default.
- W4283009251 hasAuthorship W4283009251A5031442179 @default.
- W4283009251 hasAuthorship W4283009251A5032332498 @default.
- W4283009251 hasAuthorship W4283009251A5033218952 @default.
- W4283009251 hasAuthorship W4283009251A5034269875 @default.
- W4283009251 hasAuthorship W4283009251A5054082399 @default.
- W4283009251 hasAuthorship W4283009251A5054727404 @default.
- W4283009251 hasAuthorship W4283009251A5054856356 @default.
- W4283009251 hasBestOaLocation W42830092511 @default.
- W4283009251 hasConcept C121332964 @default.
- W4283009251 hasConcept C12590561 @default.
- W4283009251 hasConcept C126322002 @default.
- W4283009251 hasConcept C1276947 @default.
- W4283009251 hasConcept C203014093 @default.
- W4283009251 hasConcept C203165030 @default.
- W4283009251 hasConcept C22070199 @default.
- W4283009251 hasConcept C2522874641 @default.
- W4283009251 hasConcept C2779134260 @default.
- W4283009251 hasConcept C2779159551 @default.
- W4283009251 hasConcept C3008058167 @default.
- W4283009251 hasConcept C32611913 @default.
- W4283009251 hasConcept C524204448 @default.
- W4283009251 hasConcept C535046627 @default.
- W4283009251 hasConcept C71924100 @default.
- W4283009251 hasConcept C72563966 @default.
- W4283009251 hasConceptScore W4283009251C121332964 @default.
- W4283009251 hasConceptScore W4283009251C12590561 @default.
- W4283009251 hasConceptScore W4283009251C126322002 @default.
- W4283009251 hasConceptScore W4283009251C1276947 @default.
- W4283009251 hasConceptScore W4283009251C203014093 @default.
- W4283009251 hasConceptScore W4283009251C203165030 @default.
- W4283009251 hasConceptScore W4283009251C22070199 @default.
- W4283009251 hasConceptScore W4283009251C2522874641 @default.
- W4283009251 hasConceptScore W4283009251C2779134260 @default.
- W4283009251 hasConceptScore W4283009251C2779159551 @default.
- W4283009251 hasConceptScore W4283009251C3008058167 @default.
- W4283009251 hasConceptScore W4283009251C32611913 @default.
- W4283009251 hasConceptScore W4283009251C524204448 @default.
- W4283009251 hasConceptScore W4283009251C535046627 @default.
- W4283009251 hasConceptScore W4283009251C71924100 @default.
- W4283009251 hasConceptScore W4283009251C72563966 @default.
- W4283009251 hasLocation W42830092511 @default.
- W4283009251 hasOpenAccess W4283009251 @default.
- W4283009251 hasPrimaryLocation W42830092511 @default.
- W4283009251 hasRelatedWork W1983816934 @default.
- W4283009251 hasRelatedWork W3048479924 @default.
- W4283009251 hasRelatedWork W3193791242 @default.
- W4283009251 hasRelatedWork W4200105028 @default.
- W4283009251 hasRelatedWork W4205534188 @default.
- W4283009251 hasRelatedWork W4224266433 @default.
- W4283009251 hasRelatedWork W4283590592 @default.
- W4283009251 hasRelatedWork W4286253331 @default.
- W4283009251 hasRelatedWork W4307547625 @default.
- W4283009251 hasRelatedWork W4311960398 @default.
- W4283009251 isParatext "false" @default.